Details of the Drug Combination

General Information of Drug Combination (ID: DCY4Q3B)

Drug Combination Name
Amonafide Aminolevulinic Acid Hydrochloride
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Amonafide   DMAH59S Aminolevulinic Acid Hydrochloride   DMWNHPC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: HCT116
Zero Interaction Potency (ZIP) Score: 0.5
Bliss Independence Score: 1.47
Loewe Additivity Score: 2.92
LHighest Single Agent (HSA) Score: 5.45

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Amonafide
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Indication(s) of Aminolevulinic Acid Hydrochloride
Disease Entry ICD 11 Status REF
Actinic keratosis EK90.0 Approved [3]
Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Protoporphyrinogen oxidase (PPOX) TTNFMS9 PPOX_HUMAN Modulator [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCT354A HT29 Investigative [1]
Adult acute myeloid leukemia DCUW1HF HL-60(TB) Investigative [1]
Adult T acute lymphoblastic leukemia DCOXEXE MOLT-4 Investigative [1]
Anaplastic large cell lymphoma DCWNOS3 SR Investigative [1]
Clear cell renal cell carcinoma DCI9PV3 A498 Investigative [1]
Large cell lung carcinoma DC1G1MF NCI-H460 Investigative [1]
Renal cell carcinoma DCN50QR SN12C Investigative [1]
Colon adenocarcinoma DC3MMRI COLO 205 Investigative [5]
Invasive ductal carcinoma DCKTNFA HS 578T Investigative [5]
Invasive ductal carcinoma DC9QZGS T-47D Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.